ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is supported by a fundamentally differentiated ANKTIVA platform that is showing biologic and clinical consistency across bladder cancer and NSCLC, with randomized and comparative data linking immune restoration to meaningful efficacy. In NSCLC, ANKTIVA plus pembrolizumab improved median PFS to 7.0 months versus 2.2 months in TPS ≥50% patients, and in bladder cancer the 80-patient papillary-only cohort delivered 12-, 24-, and 36-month DFS rates of 58.2%, 52.1%, and 38.2%, with median DFS 25.3 months. The FDA-accepted sBLA with a January 6, 2027 PDUFA date, plus BCG supply remediation and broader label potential, strengthens the view that ANKTIVA can evolve from a single-approved product into a larger bladder franchise with additional upside.

ImmunityBio is challenged by a still-early commercial profile that depends heavily on ANKTIVA’s expansion, while its valuation rests on FY34 GAAP EPS of $3.92 and assumptions that may prove optimistic for a biotech still moving toward sustained revenue generation. The thesis is weakened by multiple execution risks, including clinical setbacks in ongoing and future trials, potential delays in approvals or reimbursement, and competitive pressure from approved and emerging therapies in similar patient populations. Financially, the company may require additional capital to fund commercialization, global expansion, and pipeline development, which increases dilution and balance-sheet risk if adoption of its products disappoints.